title: Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.
abstract: Men with androgen-independent prostate cancer (AIPC) frequently have bone metastasis. The effects of chemotherapy on markers of bone metabolism have not been well characterized. We conducted a prospective study of patients with AIPC randomized in the first cycle to receive either docetaxel/estramustine or zoledronic acid, a bisphosphonate, to inhibit osteoclastic activity. Here we report the effects of therapy on markers of bone metabolism in these patients following the first cycle of therapy. Serum levels of several indices of bone remodeling were evaluated using commercial enzyme-linked immunosorbent assays. Changes in markers of bone metabolism were compared in patients receiving initial chemotherapy versus bisphosphonate. There was no significant difference in median change in any of the measured bone markers in patients given zoledronic acid when compared to chemotherapy. When comparing responders to nonresponders, overall interleukin-6 (IL-6) decreased by 35% in prostate-specific antigen responders; whereas, IL-6 levels increased by 76% in nonresponders (p = 0.03). Elevated IL-6 levels and reductions in IL-6 levels early in treatment may reflect ultimate clinical response to docetaxel-based regimens.
authors.affiliation: Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
authors.forename: Kathleen M Woods
authors.initials: KM
authors.lastname: Ignatoski
authors.forename: Judah
authors.initials: J
authors.lastname: Friedman
authors.forename: June
authors.initials: J
authors.lastname: Escara-Wilke
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Zhang
authors.forename: Stephanie
authors.initials: S
authors.lastname: Daignault
authors.forename: Rodney L
authors.initials: RL
authors.lastname: Dunn
authors.forename: David C
authors.initials: DC
authors.lastname: Smith
authors.forename: Evan T
authors.initials: ET
authors.lastname: Keller
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D015850:Interleukin-6; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D000077211:Zoledronic Acid; D017430:Prostate-Specific Antigen